medigraphic.com
Federación Mexicana de Ginecología y Obstetricia, A.C.

2016, Number 01

<< Back Next >>

Ginecol Obstet Mex 2016; 84 (01)

The effect of corifollitropin alfa on in vitro fertilization-ICSI patients with previous failure with an FSH/HMG protocol: Preliminary report in Mexico

Barroso-Villa JG, Colín-Valenzuela A, Valdespín-Fierro C, Ávila-Lombardo R, Estrada-Gutiérrez G

Language: Spanish
References: 22
Page: 7-13
PDF size: 408.94 Kb.


ABSTRACT

Background: The daily application of drugs, often in high doses, is a factor of stress for the infertile couple. During the last decade corifollitropin alpha has allowed a friendlier scheme comparable to traditional protocols (rFSH-HMG) results.
Objective: To compare the results of corifollitropin alpha in patients with a previous cycle of IVF-ICSI with traditional scheme ovarian stimulation.
Material and Method: Observational, retrospective cohort study type that infertile couples were included.
Results: No significant differences in the dose used HFRS (2023U/ total ± 712 vs 636 U/total ± 307) and serum estradiol day shooting HGCr (1972 pg/dL vs 1107 ± 1152 pg/dL ± 775). A higher pregnancy rate was found corifollitropin alpha perhaps because it was a second attempt at in vitro fertilization.
Conclusions: Reproductive outcomes in a cycle of ovarian stimulation with corifollitropin are comparable with the results of a traditional ovarian stimulation cycle. It is important to broaden the experience of the drug indication in Mexican patients.


REFERENCES

  1. The ESRHE Capri workshop group. Intracytoplasmic sperm injection (ICSI) in 2006: evidence and evolution. Human Reprod Update 2007; 13:515-126.

  2. Bosch E, Ezcurra D. Individualized controlled ovarian stimulation (iCOS): maximizing success rates for assisted reproductive technology patients. Reprod Biol Endocrinol 2011; 9: 82.

  3. Ferraretti A and Gianaroli L. The Bologna criteria for the definition of poor ovarian responders: is there a need for revision? Hum Reprod 2014; 29:1842-1845.

  4. Ferraretti AP, Marca A, Fauser BCJM, Tarlatzis B, Nargund G, Gianaroli L. ESHRE consensus on the definition of poor ovarian stimulation for in vitro fertilization: the Bologna criteria. Human Reprod 2011; 27:1616-1624.

  5. Fares FA, Suganuma N, Nishimori K, LaPolt PS, Hsueh AJ, Boime I. Design of a long acting follitropin agonist by fusing the C-terminal sequence of the chorionic gonadotropin beta subunit to the follitropin beta subunit. Proc Natl Acad Sci USA 1992;89:4304-4308.

  6. Duijkers IJ, KIipping C, Boerrigter PJ, Machielsen CSM, De Bie JJ, Voortman G. Single dose pharmacokinetics and effects on follicular growth and serum hormones of a long-acting recombinant FSH preparation (FSH-CTP) in healthy pituitary- suppressed females. Hum Reprod 2002; 17:1 987-1993.

  7. Fauser BCJM, Mannaerts BMJL, Devroyey P, Leader A, Biome I, Baird DT. Advances in recombinant DNA technology: corifollitropin alfa, a hybrid molecule with sustained follicle- stimulating activity and reduced injection frequency. Hum Reprod Update 2009; 15: 309-321.

  8. De Greef R, Struijs M, de Haan A, Marintcheva-Petrova M, Mannaerts B. Dose selection of Org 36286 (corifollitropin alfa) using pharmacokinetic and dynamic modeling and simulation. Hum Reprod. 2007; 22(suppl 1): i39.

  9. Norman R, Zegers F, Salle B, Elbers J, Heijnen E, Marintcheva M, Mannaerts B. Repeated ovarian stimulation with corifollitropin alfa in patients in a GnRH antagonist protocol: no concern for immunogenicity. Human Reprod 2011; 26:2200-2208.

  10. Devroey P. Boostanfar R, Koper NP, et al: on behalf of the Engage Investigators. A double-blind, non-inferiority RCTcomparing corifollitropin alfa and recombinant FSH during the first seven days of ovarian stimulation using a GnRH antagonist protocol. Hum Reprod 2009; 24:3063-3072.

  11. Hillensjo T on behalf of The ELONVA Ensure Study Group. A comparison of ELONVA versus daily recombinant FSH (Puregon®) in a GnRH antagonist protocol for controlled ovarian stimulation in women weighing 60 kg or less. Presented at the 25th Annual Meeting of the European Society of Human Reproduction and Embryology; June 28-July 1,2009; Amsterdam, The Netherlands.

  12. Fatemi HM, Oberyé J, Popovic-Todorovic B, Witjes H, Mannaerts B. First results with ELONVA in a long GnRH agonist protocol. (ESHRE Oral Presentation O-283) Hum Reprod. 2009; 24(suppl 1): i114.

  13. Bouloux PM, Handelsman DJ, Jockenhövel F, et al. First human exposure to FSH-CTP in hypogonadotrophic hypogonadal males. Hum Reprod 2001; 16:1592-1597.

  14. The Corifollitropin alfa Dose-finding Study Group. A randomized dose-response trial of a single injection of corifollitropin alfa to sustain multifollicular growth during controlled ovarian stimulation. Hum Reprod 2008; 23:2484-2492.

  15. Balen AH, Mulders AG, Fauser BC, et al. Pharmacodynamics of a single low dose of long-acting recombinant folliclestimulating hormone (FSH-carboxy terminal peptide, corifollitropin alfa) in women with World Health Organization Group ll anovulatory infertility. J Clin Endocrinol Metab 2004; 89:6297-6304.

  16. Beckers NG, Macklon NS, Devroey P, Platteau P, Boerrigter PJ, Fauser BC. First live birth after ovarian stimulation using a chimeric long-acting human recombinant folliclestimulating hormone (FSH) agonist (recFSH-CTP) for in vitro fertilization. Fertil Steril 2003; 79:621-623.

  17. Devroey P. Fauser BC, Platteau P, Beckers NG, Dhont M, Mannaerts BM. Induction of multiple follicular development by a single dose of long-acting recombinant folliclestimulating hormone (FSH-CTP, corifollitropin alfa) for controlled ovarian stimulation before in vitro fertilization. J Clin Endocrinol Metab 2004; 89: 2062-2070.

  18. C. Blockeel, N.P. Polyzos, L. Derksen, M. De Brucker, V. Vloeberghs, A. van de Vijver, M. De Vos, and H. Tournaye. Administration of corifollitropin alfa on Day 2 versus Day 4 of the cycle in a GnRH antagonist protocol: A randomized controlled pilot study. Hum Reprod 2014; 29: 1500-1507.

  19. Verbost P, Sloot W, Rose U, Leeuw R, Hanssen R, Verhejden G. Pharmacologic profiling of corifollitropin alfa, the fist developed sustained follicle stimulant. European J Pharmacol 2011; 651:227-233.

  20. Mahmoud Youssef MA1, van Wely M, Aboulfoutouh I, El-Khyat W, van der Veen F, Al-Inany H. Is there a place for corifollitropin alfa in IVF/ICSI cycles? A systematic review and meta-analysis. Feril Steril 2012; 97:876-885.

  21. Polyzos NP1, Devos M, Humaidan P, Stoop D, Ortega- Hrepich C, Devroey P, Tournaye H. Corifollitropin alfa followed by rFSH in a GnRH antagonist protocol for poor ovarian responder patients: an observational pilot study. Fertil Steril 2013; 99:422-427.

  22. Bonduelle M, Mannaerts B, Leader A, Bergh C, Passier D, Devroey P. Prospective follow-up of 838 fetuses conceived after ovarian stimulation with corifollitropin alfa: comparative and overall neonatal outcome. Hum Reprod 2012; 27:2177-2185.




2020     |     www.medigraphic.com